Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HIMS
HIMS logo

HIMS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
21.620
Open
21.000
VWAP
20.39
Vol
26.63M
Mkt Cap
4.52B
Low
19.700
Amount
542.80M
EV/EBITDA(TTM)
27.90
Total Shares
227.94M
EV
4.92B
EV/OCF(TTM)
16.39
P/S(TTM)
2.15
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
Show More

Events Timeline

(ET)
2026-03-31
10:30:00
FDA Moves Toward Allowing Pharmacies to Produce Banned Peptides
select
link
2026-03-31
07:50:00
Novo Nordisk Launches Wegovy Subscription Program, Save Up to $1200 Annually
select
2026-03-26 (ET)
2026-03-26
14:10:00
OpenAI Plans to Raise $10B, Nvidia-Backed Reflection Seeks $2.5B
select
2026-03-26
12:10:00
Hims & Hers Launches Novo Nordisk GLP-1 Medications
select
2026-03-12 (ET)
2026-03-12
09:00:00
Global Market Volatility and Rising Oil Prices Impact Stock Futures
select

News

stocktwits
8.5
03-31stocktwits
PinnedFDA Moves to Lift Restrictions on Peptides, Boosting Hims & Hers Shares
  • Stock Surge: Hims & Hers Health Inc. (HIMS) shares surged nearly 6% in Tuesday morning trading, primarily driven by the FDA's plan to lift restrictions on peptide drugs, reflecting market optimism about the company's growth prospects.
  • Policy Shift: According to a report by The New York Times, the FDA is considering allowing compounding pharmacies to manufacture over a dozen injectable peptides that were previously banned due to safety risks, which will create new market opportunities for companies like HIMS.
  • Market Impact: This policy reversal will end a 2023 ban on 14 peptides, meaning HIMS can re-enter this potentially lucrative market, thereby enhancing its competitiveness in the compounded medication sector.
  • Industry Outlook: With the FDA's decision, HIMS is poised to expand its product line to meet the growing customer demand, further solidifying its market position in the health tech industry.
Globenewswire
7.0
04-01Globenewswire
Hims & Hers Health Faces Legal Investigation Over Securities Violations
  • Legal Investigation Launched: The Schall Law Firm is investigating Hims & Hers Health for potential securities law violations, focusing on whether the company made false or misleading statements that could harm investors' interests.
  • FDA Statement Impact: The FDA announced its intent to restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, directly affecting Hims & Hers' market operations and potentially leading to stricter regulations.
  • Increased Litigation Risk: Hims & Hers is also facing a lawsuit from Novo Nordisk seeking to bar the sale of compounded weight loss drugs, which will further escalate the company's legal risks and could impact its market share.
  • Significant Stock Decline: Following these developments, Hims & Hers' shares fell by over 17.8% during afternoon trading on February 9, 2026, reflecting market concerns about the company's future prospects and potentially undermining investor confidence.
CNBC
8.5
04-01CNBC
Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
  • Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
  • Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
  • Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
  • Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
Newsfilter
8.5
03-31Newsfilter
Novo Nordisk Launches Wegovy Drug Subscription Program
  • Subscription Program Launch: Novo Nordisk has introduced a multi-month subscription program for its Wegovy obesity drug, aiming to provide cash-paying patients with lower, predictable monthly prices, with potential annual savings of up to $1,200.
  • Flexible Options: Patients can choose from three, six, or twelve-month subscriptions, with lower monthly fees for both the injection and the newly launched pill, priced at $329 for three months, $299 for six months, and $249 for twelve months for the injection.
  • Competitive Market Pressure: Following the explosive uptake of Novo's pill since its U.S. launch in January, it is set to face competition from Eli Lilly's upcoming oral GLP-1, which currently holds a 60% market share in the U.S.
  • Patient Support Strategy: Novo emphasizes that the subscription program not only aids patients in starting therapy but also helps them manage pricing fluctuations during treatment, aiming to enhance long-term adherence to obesity treatment.
CNBC
8.5
03-31CNBC
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
  • Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
  • Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
  • Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
  • Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
NASDAQ.COM
8.5
03-27NASDAQ.COM
Hims & Hers Launches Novo Nordisk Weight Loss Medications
  • Increased Medication Accessibility: Hims & Hers Health Inc. announced a collaboration with Novo Nordisk to make FDA-approved GLP-1 medications like Wegovy and Ozempic more accessible, potentially aiding eligible customers in losing up to 20% of their body weight, thereby significantly improving their health outcomes.
  • Diverse Dosage Options: The newly launched Wegovy medications include various dosage options such as injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, along with oral medications in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths, catering to different customer needs and enhancing market competitiveness.
  • Membership Program Launch: The company has introduced a new weight loss membership program that offers 24/7 access to healthcare providers, personalized nutrition guidance, and peer support, with an initial cost of $39 for the first month and $149 thereafter, aimed at increasing customer success rates in weight loss through comprehensive support.
  • Transparent Pricing: Medication prices start at $149 per month, and customers can utilize HSA and FSA plans to cover medication costs, enhancing payment flexibility and attracting more potential users to join the membership program.
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
Wall Street analysts forecast HIMS stock price to rise
3 Buy
6 Hold
3 Sell
Hold
Current: 0.000
sliders
Low
16.50
Averages
32.95
High
60.00
Current: 0.000
sliders
Low
16.50
Averages
32.95
High
60.00
TD Cowen
Hold
to
Hold
downgrade
$25 -> $23
AI Analysis
2026-03-27
Reason
TD Cowen
Price Target
$25 -> $23
AI Analysis
2026-03-27
downgrade
Hold
to
Hold
Reason
TD Cowen lowered the firm's price target on Hims & Hers to $23 from $25 and keeps a Hold rating on the shares. The firm hosted an investor meeting with WW management, who remain constructive on the weight-loss category, supported by continued momentum in GLP-1 medications. The company is actively investing to increase awareness of the refreshed Weight Watchers brand and to scale its evolving product portfolio.
BofA
Allen Lutz
Neutral
maintain
2026-03-26
Reason
BofA
Allen Lutz
Price Target
2026-03-26
maintain
Neutral
Reason
BofA analyst Allen Lutz notes Hims & Hers (HIMS) announced its new membership for branded Wegovy subscriptions through the recently announced NovoCare (NVO) partnership will be priced at $149 per month excluding the price of medication, which the firm calls "slightly higher than we initially expected" and modestly above peer Ro at $145 per month. The firm, which estimates Hims' GLP-1 franchise will contract by 31% in 2026, adds that this estimate "could be optimistic as HIMS moves from a position of a low cost provider to an average cost provider of GLP-1 medications." The firm maintains a Neutral rating on the stock.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for HIMS
Unlock Now

Valuation Metrics

The current forward P/E ratio for Hims & Hers Health Inc (HIMS.N) is 81.27, compared to its 5-year average forward P/E of 7.60. For a more detailed relative valuation and DCF analysis to assess Hims & Hers Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
7.60
Current PE
81.27
Overvalued PE
64.94
Undervalued PE
-49.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.20
Current EV/EBITDA
28.92
Overvalued EV/EBITDA
45.63
Undervalued EV/EBITDA
-25.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.13
Current PS
1.47
Overvalued PS
5.11
Undervalued PS
1.15

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

What is a good stock for day trade today
Intellectia · 194 candidates
Market Cap: >= 500.00MPrice: $5.00 - $100.00Price Change Pct: $3.00 - $15.00Relative Vol: >= 2Beta: HighRiskList Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
INTC logo
INTC
Intel Corp
206.50B
ONDS logo
ONDS
Ondas Inc
3.78B
NU logo
NU
Nu Holdings Ltd
65.60B
NIO logo
NIO
NIO Inc
13.68B
CDE logo
CDE
Coeur Mining, Inc
10.59B
U logo
U
Unity Software Inc
8.96B
list top 10 stocks with bullish momentum
Intellectia · 88 candidates
Market Cap: >= 2.00BRegion: USRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $10.00
Ticker
Name
Market Cap$
top bottom
AAOI logo
AAOI
Applied Optoelectronics Inc
8.89B
BW logo
BW
Babcock & Wilcox Enterprises Inc
2.11B
AHG logo
AHG
Akso Health Group
2.03B
AMPX logo
AMPX
Amprius Technologies Inc
2.46B
DNTH logo
DNTH
Dianthus Therapeutics Inc
4.02B
CVI logo
CVI
CVR Energy Inc
3.29B
create a stock picker with 1000 to spend
Intellectia · 44 candidates
Market Cap: 1000.00M - 15.00BPrice: $10.00 - $40.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMonth Price Change Pct: $10.00 - $35.00One Week Rise Prob: 0 - 100Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
BTU logo
BTU
Peabody Energy Corp
4.65B
PLSE logo
PLSE
Pulse Biosciences Inc
1.45B
PUMP logo
PUMP
ProPetro Holding Corp
1.81B
TEN logo
TEN
Tsakos Energy Navigation Ltd
1.19B
CRK logo
CRK
Comstock Resources Inc
6.27B
VECO logo
VECO
Veeco Instruments Inc
2.08B
strong short term stocks
Intellectia · 19 candidates
Market Cap: >= 5.00BRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $3.00Month Price Change Pct: >= $10.00
Ticker
Name
Market Cap$
top bottom
CZR logo
CZR
Caesars Entertainment Inc
5.71B
HIMS logo
HIMS
Hims & Hers Health Inc
5.65B
DELL logo
DELL
Dell Technologies Inc
100.48B
PBF logo
PBF
PBF Energy Inc
5.09B
CGON logo
CGON
CG Oncology Inc
5.43B
TERN logo
TERN
Terns Pharmaceuticals Inc
5.06B
Most bullish stocks over 10
Intellectia · 280 candidates
Price: >= $10.00Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00Macd: bullish
Ticker
Name
Market Cap$
top bottom
HIMS logo
HIMS
Hims & Hers Health Inc
5.90B
HIMX logo
HIMX
Himax Technologies Inc
1.60B
AXTI logo
AXTI
AXT Inc
2.62B
TENX logo
TENX
Tenax Therapeutics Inc
251.43M
XENE logo
XENE
Xenon Pharmaceuticals Inc
4.91B
BODI logo
BODI
Beachbody Company Inc
78.33M
stocks that spiked above $3 today
Intellectia · 25 candidates
Price: >= $10.00Volume: >= 1,000,000Price Change Pct: >= $8.00
Ticker
Name
Market Cap$
top bottom
NVTS logo
NVTS
Navitas Semiconductor Corp
2.50B
PZZA logo
PZZA
Papa John's International Inc
1.28B
NBIS logo
NBIS
Nebius Group NV
28.34B
SOC logo
SOC
Sable Offshore Corp
2.44B
PRCT logo
PRCT
Procept Biorobotics Corp
1.57B
PTRN logo
PTRN
Pattern Group Inc
2.20B
what should I say trade today stocks wise
Intellectia · 79 candidates
Price: $5.00 - $150.00Volume: >= 1,000,000Price Change Pct: $2.00 - $15.00Beta: HighRiskList Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
PATH logo
PATH
UiPath Inc
6.20B
HIMS logo
HIMS
Hims & Hers Health Inc
5.35B
INTC logo
INTC
Intel Corp
233.62B
OPEN logo
OPEN
Opendoor Technologies Inc
4.80B
IREN logo
IREN
IREN Ltd
12.67B
WULF logo
WULF
Terawulf Inc
6.09B
one day increase of at least 2 percent
Intellectia · 453 candidates
Region: USPrice Change Pct: >= $2.00
Ticker
Name
Market Cap$
top bottom
ASNS logo
ASNS
Actelis Networks Inc
3.29M
ACXP logo
ACXP
Acurx Pharmaceuticals Inc
7.39M
GSUN logo
GSUN
Golden Sun Technology Group Ltd
5.08M
CVGI logo
CVGI
Commercial Vehicle Group Inc
59.50M
KALA logo
KALA
KALA BIO Inc
267.84M
SOS logo
SOS
Sos Ltd
12.07M
What stocks are trending for daytrading?
Intellectia · 310 candidates
Region: USPrice: $0.50 - $80.00Relative Vol: >= 1.30Beta: ModerateRisk, HighRiskIs Optionable: TrueMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
NIO logo
NIO
NIO Inc
14.15B
AAL logo
AAL
American Airlines Group Inc
7.34B
HIMS logo
HIMS
Hims & Hers Health Inc
5.35B
RIVN logo
RIVN
Rivian Automotive Inc
20.53B
PATH logo
PATH
UiPath Inc
6.20B
WIT logo
WIT
Wipro Ltd
26.72B
5 stocks under $20 to t22rade everyday
Intellectia · 1186 candidates
Price: $1.00 - $20.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEWeekly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
KVUE logo
KVUE
Kenvue Inc
35.52B
HIMS logo
HIMS
Hims & Hers Health Inc
3.80B
SOFI logo
SOFI
SoFi Technologies Inc
26.11B
F logo
F
Ford Motor Co
55.19B
U logo
U
Unity Software Inc
9.27B
WULF logo
WULF
Terawulf Inc
6.71B

Whales Holding HIMS

H
Himension Capital (Singapore) Pte Ltd
Holding
HIMS
-0.91%
3M Return
D
Divisadero Street Capital Management, LP
Holding
HIMS
-5.64%
3M Return
F
Farallon Capital Management, L.L.C.
Holding
HIMS
-6.04%
3M Return
T
The State of Michigan Retirement Systems
Holding
HIMS
-6.10%
3M Return
C
Cantor Fitzgerald Asset Management
Holding
HIMS
-6.31%
3M Return
S
Summit Trail Advisors, LLC
Holding
HIMS
-7.79%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Hims & Hers Health Inc (HIMS) stock price today?

The current price of HIMS is 19.84 USD — it has decreased -4.43

What is Hims & Hers Health Inc (HIMS)'s business?

Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.

What is the price predicton of HIMS Stock?

Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is32.95 USD with a low forecast of 16.50 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Hims & Hers Health Inc (HIMS)'s revenue for the last quarter?

Hims & Hers Health Inc revenue for the last quarter amounts to 617.82M USD, increased 28.41

What is Hims & Hers Health Inc (HIMS)'s earnings per share (EPS) for the last quarter?

Hims & Hers Health Inc. EPS for the last quarter amounts to 0.08 USD, decreased -27.27

How many employees does Hims & Hers Health Inc (HIMS). have?

Hims & Hers Health Inc (HIMS) has 2442 emplpoyees as of April 02 2026.

What is Hims & Hers Health Inc (HIMS) market cap?

Today HIMS has the market capitalization of 4.52B USD.